We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Introduction to Vaccines
-
1. History of vaccines
- Prof. Stanley Plotkin
-
2. The science of vaccine adjuvants
- Dr. Derek O'Hagan
-
3. Vaccine preclinical studies 1
- Dr. Rebecca Sheets
-
4. Vaccine preclinical studies 2
- Dr. Rebecca Sheets
-
5. Vaccine manufacturing 1
- Dr. Don Gerson
-
6. Vaccine manufacturing 2
- Dr. Don Gerson
-
10. Recommendations of the U.S. advisory committee on immunization practices
- Prof. Jonathan Temte
- Vaccines in Development
-
11. HIV vaccine development
- Dr. Patricia Fast
-
12. Developing tuberculosis vaccines - challenges and strategies 1
- Dr. Thomas Evans
-
13. Developing tuberculosis vaccines - challenges and strategies 2
- Dr. Thomas Evans
-
14. Malaria vaccine development 1
- Dr. Ashley Birkett
-
15. Malaria vaccine development 2
- Dr. Ashley Birkett
-
16. Dengue vaccine development: l. status
- Prof. Scott Halstead
-
17. Dengue vaccine development: II. problems to be solved
- Prof. Scott Halstead
-
18. Respiratory syncytial virus vaccination
- Prof. Peter Openshaw
-
19. Herpes simplex virus vaccines
- Prof. Lawrence Stanberry
-
20. Bacterial vaccines in development 1
- Dr. Kathrin Jansen
-
21. Bacterial vaccines in development 2
- Dr. Kathrin Jansen
-
22. Biodefense and special pathogen vaccines in development 1
- Dr. Gerald Kovacs
-
23. Biodefense and special pathogen vaccines in development 2
- Dr. Gerald Kovacs
-
24. Cancer vaccines 1
- Prof. Cornelis Melief
-
25. Cancer vaccines 2
- Prof. Cornelis Melief
- Future Directions for Vaccine Development
-
26. Replication-competent viral vectors
- Dr. Farshad Guirakhoo
-
27. Vector mediated immunoprophylaxis
- Dr. Bruce Schnepp
-
28. Future directions for vaccine discovery 1
- Dr. Chris Wilson
-
29. Future directions for vaccine discovery 2
- Dr. Chris Wilson
- Archived Lectures *These may not cover the latest advances in the field
-
30. Vaccine adjuvants 1
- Dr. Derek O'Hagan
-
31. Vaccine adjuvants 2
- Dr. Derek O'Hagan
-
32. Respiratory syncytial virus vaccine development
- Prof. Peter Openshaw
Printable Handouts
Navigable Slide Index
- Introduction
- Overview
- Community vaccine development goals
- Starting with the end in mind
- CHMI models facilitate ‘shifting to the left’
- Overview : Malaria vaccine TRM goals
- Progress against TRM goals
- RTS,S/AS01 vaccine candidate
- RTS,S/AS01: phase 2a CHMI efficacy results
- Phase 2a CHMI immunogenicity results
- RTS,S/AS01: key phase 2b pediatric data
- RTS,S/AS01 phase 3 trial
- RTS,S/AS01 phase 3 study population
- RTS,S/AS01 phase 3 study design
- RTS,S/AS01 phase 3 vaccine efficacy and safety
- RTS,S/AS01 next steps
- Progress against TRM: Goal 1
- Global malaria vaccine pipeline (1)
- De-risking asexual blood-stage vaccine
- Objectives for blood-stage CHMI study
- AMA1/AS01 GIA results
- AMA1/AS01 efficacy results
- Progress against TRM: Goal 2
- A critical gap in control interventions
- Replicating natural immunity is not the solution
- Targeting lifecycle bottlenecks
- Global malaria vaccine pipeline (2)
- Bridges to clinical benefit (1)
- Leading target antigens
- Target identification study in mice
- Comparison of Pfs25 candidates in NHPs
- High-level transmission reducing activity in NHPs
- Promising NHP results not replicated in humans
- Bridges to clinical benefit (2)
- To evaluate human-to-mosquito transmission
- Experimental P. vivax blood-stage (parasitemia)
- Experimental P. vivax blood-stage
- Summary
- Thank you
Topics Covered
- Community vaccine development goals
- Increasing probability of success and reducing risk
- Progress against malaria vaccine technology roadmap goals
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Birkett, A. (2015, June 22). Malaria vaccine development 2 [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved March 13, 2025, from https://doi.org/10.69645/PFNB5940.Export Citation (RIS)
Publication History
- Published on June 22, 2015
Financial Disclosures
- Dr. Ashley Birkett has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Malaria vaccine development 2
Published on June 22, 2015
46 min
A selection of talks on Immunology & Inflammation
Transcript
Please wait while the transcript is being prepared...
0:04
So that completes the first
part of the talk, the introduction.
Now I'm going to go down
into vaccine development efforts
in three main sections.
I'm going to focus initially on
our community vaccine development
goals, I expressed that there
clearly is an unmet medical
need in malaria for a vaccine.
But it's very important that we
target our vaccine development
efforts in an appropriate way
to develop the type of tools
that the community is going to
need to help mitigate the burden
of malaria going forward.
And then I added a few slides
on increasing the probability
of success in reducing risk.
We're in a very resource-constrained
environment in terms
of malaria product development.
These vaccines are intended
for the poorest of the poor.
There's not a high profit
to be made in developing
these types of vaccines.
We're targeting the parasite
here, very difficult to develop
vaccines against parasites.
There are currently no licensed
vaccines against human parasites.
So this is challenging work.
The payoffs are modest.
The risk is high.
So we have to be very prudent
in terms of how we use
the limited resources and make sure
that we're doing everything we can
early in development to
reduce risk and ensure
that we're only investing in
candidates that have the highest
possible probability of success.
And I'm going to touch on that a
little bit in the next few slides.
We have some great tools in malaria
vaccine development that really do
put us at an advantage, and I
think give us a great confidence
that we will be able to
develop highly effective
vaccines over the coming years.
And then to finish, I will
talk about the progress
against these community
goals as things stand today,
with a particular
emphasis on these tools
that we use to make the
most robust decisions
that we can going forward.